Ireland· IE-PA-PA2206/001/001
Rifaximin Alfasigma 550 mg film-coated tablets
A rifaximin product containing rifaximin, registered in Ireland by Alfasigma S.p.A. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Rifaximin is registered in 14 of 19 countries.
Countries holding a registration under ATC A07AA11 (rifaximin), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Rifaximin · ATC A07AA11
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rifaximin costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rifaximin · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.02
The record
At a glance
HPRA (Ireland)- Active substance
- Rifaximin
- Manufacturer
- Alfasigma S.p.A
- Country
- Ireland (IE)
- ATC code
- A07AA11
- ATC class
- Rifaximin
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA2206/001/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
88 interactions on record for rifaximin.
Graded by severity as the source publishes them — 63 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rifaximin · interactions on record
88 records
- 63 moderate
- 25 info
Most severe, free to view
- RolapitantA04AD14moderate
- Sodium picosulfateA06AB08moderate
- EliglustatA16AX10moderate
- LonafarnibA16AX20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rifaximin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandReferoALFASIGMA S.p.A.
- SwedenXifaxan 550 mg Filmdragerad tablettNorgine BV
- NetherlandsTIXTELLER 550 mg filmomhulde tablettenAlfasigma S.p.A.
- BelgiumTargaxan 550 mgNorgine
- SwitzerlandXifaxan 550 mg, FilmtablettenAlfasigma Schweiz AG
- SpainTIXTAR 550 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAlfasigma S.P.A.
- NorwayRifaximin Aurora Medical2care4 ApS
- FranceTIXTAR 550 mg, comprimé pelliculéALFASIGMA FRANCE
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Colidimin, Refero
- Belgium · Targaxan, Tixteller
- Czechia · Normix
- Germany · Rifaxan, Tixteller
- Denmark · Faxinorm, Xifaxan
- Spain · Spiraxin, Tixtar
- Finland · Targaxan, Xifaxan
- France · Tixtar
- United Kingdom (Northern Ireland) · Normicron, Rifaximin
- Greece · Rifacol
- Hungary · Normix, Refero
- Italy · Flonorm, Normix
- Luxembourg · Refero, Targaxan
- Netherlands · Tixteller, Xifaxan
- Norway · Xifaxan
- Poland · Tixteller, Xifaxan
- Portugal · Refero, Xifaxan
- Romania · Normix, Tixteller
- Sweden · Xifaxan
- Slovakia · Normix, Refero
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bdcdba11-328e-4e99-96c6-833e7c0abd17 GET /v1/drugs/bdcdba11-328e-4e99-96c6-833e7c0abd17?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A07AA",
"A07AA11"
],
"strength": null,
"pa_number": "PA2206/001/001",
"substances": [
"Rifaximin"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Not marketed",
"authorised_at": "18/12/2012",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about rifaximin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.